Background: Up to 95% of irradiated patients suffer from ionizing radiation (IR) induced early skin reaction, acute radiation dermatitis (ARD). Some experts think that additional skin hydration can reduce acute skin reactions. Individual radiosensitivity (IRS) determined from lymphocytes may help to predict acute radiation toxicity. The purpose of this study is to evaluate the clinical manifestation of ARD in different skincare groups during whole breast radiotherapy depending on IRS and other risk factors.
Methods: A total of 108 early-stage breast cancer patients were randomized into best supportive care (BSC) and additional skincare (ASC) groups. IRS was evaluated using a G2 assay modified with caffeine-induced G2 checkpoint arrest. All patients received a 50 Gy dose to the breast planning target volume (PTV). Clinical assessment of ARD symptoms according to the CTCAE grading scale was performed once a week.
Results: IRS was successfully determined for 91 out of 108 patients. A total of 10 patients (11%) had normal IRS, 47 patients (52%) were categorized as radiosensitive, and 34 (37%) as highly radiosensitive. There was no significant difference in the manifestation of ARD between patient groups by skincare or IRS. According to logistic regression, patients with bigger breasts were prone to more severe ARD ( = 0.002).
Conclusions: The additional skincare did not improve skin condition during RT. A total of 89% of patients had increased radiosensitivity. IRS determined before RT did not show the predictive value for the manifestation of ARD. Logistic regression revealed that breast volume was the most significant risk factor for the manifestation of ARD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781761 | PMC |
| http://dx.doi.org/10.3390/life12010020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study.
Ann Rheum Dis
November 2024
University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
Article Synopsis
- The study aimed to clarify inconsistent findings regarding the gut bacteria Prevotellaceae and its role in rheumatoid arthritis (RA) by comparing gut microbiome changes in individuals who progressed to RA against those who did not.
- Researchers tracked participants at risk of RA over 15 months, discovering significant differences in Prevotellaceae levels and overall gut microbiome instability in those who progressed to RA, occurring approximately 10 months before RA symptoms appeared.
- The findings suggest that changes in the gut microbiome, particularly involving Prevotellaceae, may be linked to RA development, but it remains uncertain whether these changes initiate the disease or are a result of it.
Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signatures.
Ann Rheum Dis
October 2024
U1227, LBAI, Univ Brest, Inserm, and CHU Brest, Brest, France, Brest, France
Article Synopsis
- Systemic sclerosis (SSc) is a complicated disease with various manifestations, making it hard to manage, but autoantibodies may help identify different patient groups and their underlying mechanisms.
- A study of 206 SSc patients used antibody status (ACA and SCL70) and various biological analyses to explore differences between groups.
- Results showed that SCL70-positive patients had more severe symptoms and unique biological profiles, while ACA-positive patients had a different set of immune and metabolic features, highlighting the importance of serological status in understanding and treating the disease.
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial.
Ann Rheum Dis
October 2024
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Introduction: Evidence from randomised controlled trials on anti-tumour necrosis factor (TNF) agents in patients with Behçet's syndrome (BS) is low.
Method: We conducted a phase 3, multicentre, prospective, randomised, active-controlled, parallel-group study to evaluate the efficacy and safety of either infliximab (IFX) or adalimumab (ADA) in patients with BS. Adults patients with BS presenting with active mucocutaneous manifestations, occurring while on therapy with either azathioprine or cyclosporine for at least 3 months prior to study entry, were eligible.
High rate of detected variants in male and genes causing failed fertilization after ICSI.
Hum Reprod Open
September 2024
Ghent-Fertility And Stem cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Ghent, Belgium.
Article Synopsis
- * Previous research has linked certain genetic variants to fertilization issues in ICSI, highlighting the need for larger studies to gauge how often these variants appear and their impact on calcium release during oocyte activation.
- * The study involved two cohorts where genetic screenings were performed, with one group receiving comprehensive screening and both groups having low previous fertilization rates; they tested a technique to better activate oocytes and hopefully
EULAR recommendations for the treatment of systemic sclerosis: 2023 update.
Ann Rheum Dis
October 2024
Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France.
Article Synopsis
- A team updated the 2017 EULAR treatment recommendations for systemic sclerosis (SSc) to include new evidence and therapy options.
- They conducted a systematic literature review and developed 22 recommendations across 8 clinical areas, focusing mainly on skin fibrosis and interstitial lung disease (ILD).
- The updated guidelines now suggest new treatments like mycophenolate mofetil and rituximab and emphasize a research agenda for future therapies targeting various aspects of SSc.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!